QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
$0.05
$0.07
$0.11
$5.00
$5.60M-1.922,942 shsN/A
Selectis Health, Inc. stock logo
GBCS
Selectis Health
$2.00
$2.23
$1.05
$6.25
$6.13M-0.36972 shsN/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
$0.07
+0.7%
$0.09
$0.06
$0.17
$7.89M0.0733,906 shs12,000 shs
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$9.00
+6.5%
$8.50
$4.35
$9.32
$16.38M1.747,724 shs7,693 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
0.00%0.00%-38.35%-50.00%-75.25%
Selectis Health, Inc. stock logo
GBCS
Selectis Health
+33.33%+33.33%+33.33%-46.67%-55.56%
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
+0.71%-7.24%-19.89%-45.77%-36.54%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
+6.51%+6.38%-1.85%+12.36%+29.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Selectis Health, Inc. stock logo
GBCS
Selectis Health
N/AN/AN/AN/AN/AN/AN/AN/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.2543 of 5 stars
0.54.00.00.00.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
N/AN/AN/AN/A
Selectis Health, Inc. stock logo
GBCS
Selectis Health
N/AN/AN/AN/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
1.00
Sell$5.00-44.44% Downside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
$310K18.07N/AN/A($0.01) per share-5.00
Selectis Health, Inc. stock logo
GBCS
Selectis Health
$36.78MN/AN/AN/A$0.06 per shareN/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
$1.87M4.22N/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$2.13M7.69N/AN/A$37.95 per share0.24

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
-$1.36MN/A0.00N/A-299.54%N/A-425.51%N/A
Selectis Health, Inc. stock logo
GBCS
Selectis Health
-$2.40M-$1.30N/AN/A-6.59%-159.15%-5.61%5/14/2024 (Estimated)
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
-$3.96M-$0.06N/AN/A-194.80%-717.03%-326.30%6/12/2024 (Estimated)
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
-$62.01M-$34.18N/AN/A-2,905.67%-69.49%-54.15%5/9/2024 (Estimated)

Latest PURE, ATMS, TLIS, and GBCS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q2 2024
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/A-$0.01-$0.01-$0.01N/A$0.33 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
N/AN/AN/AN/AN/A
Selectis Health, Inc. stock logo
GBCS
Selectis Health
N/AN/AN/AN/AN/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
N/A
0.15
0.12
Selectis Health, Inc. stock logo
GBCS
Selectis Health
N/A
0.40
0.40
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
3.75
1.72
1.59
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/A
8.86
8.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
N/A
Selectis Health, Inc. stock logo
GBCS
Selectis Health
N/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
43.77%

Insider Ownership

CompanyInsider Ownership
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
7.45%
Selectis Health, Inc. stock logo
GBCS
Selectis Health
15.20%
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
41.76%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
46.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Artemis Therapeutics Inc. stock logo
ATMS
Artemis Therapeutics
1112.03 million103.69 millionNot Optionable
Selectis Health, Inc. stock logo
GBCS
Selectis Health
671N/AN/ANot Optionable
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
11111.86 million65.15 millionNot Optionable
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
1021.82 million984,000No Data

PURE, ATMS, TLIS, and GBCS Headlines

SourceHeadline
Talis Biomedical Corporation (TLIS)Talis Biomedical Corporation (TLIS)
finance.yahoo.com - March 31 at 8:16 AM
Grabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical CorporationGrabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical Corporation
markets.businessinsider.com - February 16 at 8:42 PM
TLIS Feb 2024 2.500 putTLIS Feb 2024 2.500 put
finance.yahoo.com - February 15 at 2:52 AM
Peninsula diagnostics company to close Redwood City labs and offices, pursue strategic alternativesPeninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives'
bizjournals.com - November 14 at 8:38 PM
Talis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashTalis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
finanznachrichten.de - November 14 at 3:36 PM
LICY, BTAI and HROW among mid-day moversLICY, BTAI and HROW among mid-day movers
msn.com - November 14 at 3:36 PM
Talis reviewing strategic alternatives, stock rallies 35%Talis reviewing strategic alternatives, stock rallies 35%
msn.com - November 14 at 3:36 PM
Why Talis Biomedical (TLIS) Stock Is Exploding HigherWhy Talis Biomedical (TLIS) Stock Is Exploding Higher
msn.com - November 14 at 3:36 PM
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashTalis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
finance.yahoo.com - November 14 at 3:36 PM
Biomedical Engineering (BME) and Biomedical Science (BMS) ProgramsBiomedical Engineering (BME) and Biomedical Science (BMS) Programs
drexel.edu - October 23 at 1:39 AM
BTIG Maintains Talis Biomedical (TLIS) Sell RecommendationBTIG Maintains Talis Biomedical (TLIS) Sell Recommendation
msn.com - August 16 at 3:29 PM
BTIG Maintains Sell Rating for Talis Biomedical: Heres What You Need To KnowBTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To Know
markets.businessinsider.com - August 16 at 3:29 PM
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business UpdateTalis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
finance.yahoo.com - August 11 at 12:45 AM
A Preview Of Talis Biomedicals EarningsA Preview Of Talis Biomedical's Earnings
benzinga.com - August 9 at 2:02 PM
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
finance.yahoo.com - August 3 at 12:25 PM
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
finance.yahoo.com - August 2 at 12:20 PM
TLIS - Talis Biomedical CorporationTLIS - Talis Biomedical Corporation
uk.finance.yahoo.com - August 1 at 4:18 PM
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price RequirementTalis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
finance.yahoo.com - July 24 at 10:12 AM
Talis Biomedical Announces 1-for-15 Reverse Stock SplitTalis Biomedical Announces 1-for-15 Reverse Stock Split
finance.yahoo.com - July 5 at 9:12 AM
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent DirectorTalis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
finance.yahoo.com - May 23 at 1:12 PM
Talis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial ResultsTalis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
finanznachrichten.de - May 12 at 8:33 AM
Talis Biomedical reports Q1 resultsTalis Biomedical reports Q1 results
seekingalpha.com - May 11 at 8:53 PM
Talis Biomedical: Q1 Earnings InsightsTalis Biomedical: Q1 Earnings Insights
msn.com - May 11 at 8:53 PM
Talis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of ShareholdersTalis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of Shareholders
benzinga.com - May 9 at 1:50 PM

Media Sentiment Over Time

Company Descriptions

Artemis Therapeutics logo

Artemis Therapeutics

OTCMKTS:ATMS
Artemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.
Selectis Health logo

Selectis Health

OTCMKTS:GBCS
Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.
PURE Bioscience logo

PURE Bioscience

OTCMKTS:PURE
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Talis Biomedical logo

Talis Biomedical

NASDAQ:TLIS
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.